Tom 7, Nr 2 (2021)
Artykuł przeglądowy
Opublikowany online: 2021-09-08
Wyświetlenia strony
231
Wyświetlenia/pobrania artykułu
168
Nebiwolol w terapii pacjentów z przewlekłymi zespołami wieńcowymi
Nadciśnienie Tętnicze w Praktyce 2021;7(2):63-70.
Streszczenie
Beta-adrenolityki stanowią kluczową grupę leków w terapii pacjentów z przewlekłym zespołem wieńcowym (CCS). Wyróżniającym się przedstawicielem tej grupy jest nebiwolol. Charakteryzuje się on m.in. licznymi właściwościami plejotropowymi, najwyższą kardioselektywnością (selektywna blokada receptorów β-1) i wpływem na poprawę funkcji śródbłonka poprzez zwiększenie syntezy tlenku azotu. Nebiwolol skutecznie poprawia funkcję skurczową i rozkurczową miokardium, co sprawia, że jest lekiem preferowanym u pacjentów z towarzyszącą niewydolnością serca. Nebiwolol umożliwia także adekwatną kontrolę powszechnych u pacjentów z CCS czynników ryzyka zdarzeń sercowo-naczyniowych, takich jak podwyższone ciśnienie tętnicze i zwiększona częstość rytmu serca.
W niniejszym opracowaniu przedstawiono dowody naukowe potwierdzające skuteczność nebiwololu w terapii pacjentów z CCS.
Słowa kluczowe: przewlekły zespół wieńcowyβ-adrenolitykMINOKAwłaściwości plejotropowekardioselektywnośćdławica
Referencje
- Toblli JE, DiGennaro F, Giani JF, et al. Nebivolol: impact on cardiac and endothelial function and clinical utility. Vasc Health Risk Manag. 2012; 8: 151–160.
- Van de Water A, Janssens W, Van Neuten J, et al. Pharmacological and hemodynamic profile of nebivolol, a chemically novel, potent, and selective beta 1-adrenergic antagonist. J Cardiovasc Pharmacol. 1988; 11(5): 552–563.
- Sorrentino SA, Doerries C, Manes C, et al. Nebivolol exerts beneficial effects on endothelial function, early endothelial progenitor cells, myocardial neovascularization, and left ventricular dysfunction early after myocardial infarction beyond conventional β1-blockade. J Am Coll Cardiol. 2011; 57(5): 601–611.
- McEniery CM, Schmitt M, Qasem A, et al. Nebivolol increases arterial distensibility in vivo. Hypertension. 2004; 44(3): 305–310.
- Knuuti J, Wijns W, Saraste A, et al. ESC Scientific Document Group. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2020; 41(3): 407–477.
- Makolkin VI, Akhmedova OO, Buval'tsev VI, et al. [Clinical and metabolic effects of cardioselective beta-adrenoblockers nebivolol and metoprolol in patients with hypertension and ischemic heart disease associated with type 2 diabetes]. Kardiologiia. 2003; 43(2): 40–43.
- Rizos E, Bairaktari E, Kostoula A, et al. The combination of nebivolol plus pravastatin is associated with a more beneficial metabolic profile compared to that of atenolol plus pravastatin in hypertensive patients with dyslipidemia: a pilot study. J Cardiovasc Pharmacol Ther. 2003; 8(2): 127–134.
- Diehl KJ, Stauffer BL, Dow CA, et al. Chronic Nebivolol Treatment Suppresses Endothelin-1-Mediated Vasoconstrictor Tone in Adults With Elevated Blood Pressure. Hypertension. 2016; 67(6): 1196–1204.
- Fongemie J, Felix-Getzik E. A Review of Nebivolol Pharmacology and Clinical Evidence. Drugs. 2015; 75(12): 1349–1371.
- Brixius K, Bundkirchen A, Bölck B, et al. Nebivolol, bucindolol, metoprolol and carvedilol are devoid of intrinsic sympathomimetic activity in human myocardium. Br J Pharmacol. 2001; 133(8): 1330–1338.
- Belsey J, Savelieva I, Mugelli A, et al. Relative efficacy of antianginal drugs used as add-on therapy in patients with stable angina: A systematic review and meta-analysis. Eur J Prev Cardiol. 2015; 22(7): 837–848.
- Peller M, Ozierański K, Balsam P, et al. Influence of beta-blockers on endothelial function: A meta-analysis of randomized controlled trials. Cardiol J. 2015; 22(6): 708–716.
- Tamis-Holland JE, Jneid H, Reynolds HR, et al. American Heart Association Interventional Cardiovascular Care Committee of the Council on Clinical Cardiology; Council on Cardiovascular and Stroke Nursing; Council on Epidemiology and Prevention; and Council on Quality of Care and Outcomes Research. Contemporary Diagnosis and Management of Patients With Myocardial Infarction in the Absence of Obstructive Coronary Artery Disease: A Scientific Statement From the American Heart Association. Circulation. 2019; 139(18): e891–e908.
- Pacheco Claudio C, Quesada O, Pepine CJ, et al. Why names matter for women: MINOCA/INOCA (myocardial infarction/ischemia and no obstructive coronary artery disease). Clin Cardiol. 2018; 41(2): 185–193.
- Balsam P, Peller M, Borodzicz S, et al. In-hospital heart rate reduction and its relation to outcomes of heart failure patients with sinus rhythm: Results from the Polish part of the European Society of Cardiology Heart Failure Pilot and Long-Term Registries. Cardiol J. 2020; 27(1): 25–37.
- Kapłon-Cieślicka A, Balsam P, Ozierański K, et al. Resting heart rate at hospital admission and its relation to hospital outcome in patients with heart failure. Cardiol J. 2014; 21(4): 425–433.
- Nanchen D, Leening MJG, Locatelli I, et al. Resting heart rate and the risk of heart failure in healthy adults: the Rotterdam Study. Circ Heart Fail. 2013; 6(3): 403–410.
- Pfister R, Michels G, Sharp SJ, et al. Resting heart rate and incident heart failure in apparently healthy men and women in the EPIC-Norfolk study. Eur J Heart Fail. 2012; 14(10): 1163–1170.
- Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Kardiol Pol. 2019; 77(2): 71–159.
- Ozierański K, Kapłon-Cieślicka A, Balsam P, et al. Effect of β-blockers on 1-year survival and hospitalizations in patients with heart failure and atrial fibrillation: results from ESC-HF Pilot and ESC-HF Long-Term Registry. Pol Arch Intern Med. 2018; 128(11): 649–657.
- Ponikowski P, Voors A, Anker S, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2016; 37(27): 2129–2200.
- Nebilet. Charakterystyka Produktu Leczniczego.
- López-Sendón J, Swedberg K, McMurray J, et al. Task ForceOn Beta-Blockers of the European Society of Cardiology. Expert consensus document on beta-adrenergic receptor blockers. Eur Heart J. 2004; 25(15): 1341–1362.
- Shu DeF, Dong BiR, Lin XF, et al. Long-term beta blockers for stable angina: systematic review and meta-analysis. Eur J Prev Cardiol. 2012; 19(3): 330–341.
- Arosio E, De Marchi S, Prior M, et al. Effects of nebivolol and atenolol on small arteries and microcirculatory endothelium-dependent dilation in hypertensive patients undergoing isometric stress. J Hypertens. 2002; 20(9): 1793–1797.
- Pasini AF, Garbin U, Stranieri C, et al. Nebivolol treatment reduces serum levels of asymmetric dimethylarginine and improves endothelial dysfunction in essential hypertensive patients. Am J Hypertens. 2008; 21(11): 1251–1257.
- Lekakis JP, Protogerou A, Papamichael C, et al. Effect of nebivolol and atenolol on brachial artery flow-mediated vasodilation in patients with coronary artery disease. Cardiovasc Drugs Ther. 2005; 19(4): 277–281.
- Bouras G, Deftereos S, Tousoulis D, et al. Asymmetric Dimethylarginine (ADMA): a promising biomarker for cardiovascular disease? Curr Top Med Chem. 2013; 13(2): 180–200.
- Kandavar R, Higashi Y, Chen W, et al. The effect of nebivolol versus metoprolol succinate extended release on asymmetric dimethylarginine in hypertension. J Am Soc Hypertens. 2011; 5(3): 161–165.
- Serg M, Kampus P, Kals J, et al. Nebivolol and metoprolol: long-term effects on inflammation and oxidative stress in essential hypertension. Scand J Clin Lab Invest. 2012; 72(5): 427–432.
- Kampus P, Serg M, Kals J, et al. Differential effects of nebivolol and metoprolol on central aortic pressure and left ventricular wall thickness. Hypertension. 2011; 57(6): 1122–1128.
- Ignjatovic V, Pavlovic S, Miloradovic V, et al. Influence of Different β-Blockers on Platelet Aggregation in Patients With Coronary Artery Disease on Dual Antiplatelet Therapy. J Cardiovasc Pharmacol Ther. 2016; 21(1): 44–52.
- Karabacak M, Dogan A, Aksoy F, et al. Both carvedilol and nebivolol may improve platelet function and prothrombotic state in patients with nonischemic heart failure. Angiology. 2014; 65(6): 533–537.
